AGI Dermatics: DNA Science for Skin
Contact Us
About UsCosmetic IngredientsPharmaceutical ProductsRemergentPressBusiness DevelopmentCareers
Dimericine®
DNA Repair
Enzyme Delivery
Clinical Trials

Clinical Trials

Dimericine® is in clinical studies for several different aspects of skin cancer:

  • Xeroderma Pigmentosum Patients: Phase 3
    Phase 3 (safety and efficacy) studies have been completed in xeroderma pigmentosum (XP), the rare genetic disease with high rates of skin cancer at a young age.
  • Renal Transplant Patients: Phase 2
    Dimericine is in Phase 2 (activity) studies for prevention of skin cancer in renal transplant patients, who have elevated rates of skin cancer.
  • At-Risk Population: Phase 2
    Dimericine is about to enter Phase 2 studies for the at-risk population, which consists of people who have a history of skin cancer or pre-skin cancer.